XEN1101, marks a significant leap forward in the realm of precision medicine for drug-resistant epilepsy, as unlike current treatments that necessitate gradual dosage adjustments, XEN1101 offers the advantage of safe initiation at optimal dosage right from the start.
XEN1101 unveils compelling efficacy with a statistically significant reduction of at least 50% in seizure frequency for patients with focal epilepsy spanning a spectrum of disease severity, by regulating potassium channels to stabilize neuronal excitability
Focal-onset seizures (FOS), the predominant seizure type encountered in individuals with epilepsy, remain inadequately managed with exis...
